(MedPage Today) — Despite substantial health benefits, two GLP-1 receptor agonists weren’t cost-effective at their current prices, according to an economic evaluation that compared four anti-obesity medications.
Net prices of tirzepatide (Mounjaro…
Source link
High Price of GLP-1 Agents Tip Cost-Benefit Scale Unfavorably
